Literature DB >> 17229908

Clinical aspects of iron use in the anemia of kidney disease.

Walter H Hörl1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17229908     DOI： 10.1681/ASN.2006080856

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  40 in total

Review 1.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  Anemia in elderly hospitalized patients: prevalence and clinical impact.

Authors:  Margherita Migone De Amicis; Erika Poggiali; Irene Motta; Francesca Minonzio; Giovanna Fabio; Cinzia Hu; Maria Domenica Cappellini
Journal:  Intern Emerg Med       Date:  2015-01-30       Impact factor: 3.397

Review 3.  [Iron deficiency : Recognition and treatment].

Authors:  S von Haehling; H Ottenjann; S D Anker
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

4.  Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.

Authors:  Lavinia Oltiţa Brătescu; Liliana Bârsan; Liliana Gârneaţă; Ana Stanciu; Mariana Lipan; Simona Hildegard Stancu; Gabriel Mircescu
Journal:  Int Urol Nephrol       Date:  2014-03-29       Impact factor: 2.370

5.  Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.

Authors:  Hassan N Ibrahim; Robert N Foley; Rui Zhang; David T Gilbertson; Allan J Collins
Journal:  Clin J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 8.237

6.  Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients.

Authors:  Ko-Lin Kuo; Szu-Chun Hung; Yau-Huei Wei; Der-Cherng Tarng
Journal:  J Am Soc Nephrol       Date:  2008-05-21       Impact factor: 10.121

Review 7.  Safety issues with intravenous iron products in the management of anemia in chronic kidney disease.

Authors:  Amir Hayat
Journal:  Clin Med Res       Date:  2008-12

8.  Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD.

Authors:  Ko-Lin Kuo; Szu-Chun Hung; Tzong-Shyuan Lee; Der-Cherng Tarng
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

9.  Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.

Authors:  Kamyar Kalantar-Zadeh; Grace H Lee; Jessica E Miller; Elani Streja; Jennie Jing; John A Robertson; Csaba P Kovesdy
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

10.  At pharmacologically relevant concentrations intravenous iron preparations cause pancreatic beta cell death.

Authors:  Yuichi Masuda; Hirohito Ichii; Nosratola D Vaziri
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.